A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors

Adjei, AA; LoRusso, P; Ribas, A; Sosman, JA; Pavlick, A; Dy, GK; Zhou, XF; Gangolli, E; Kneissl, M; Faucette, S; Neuwirth, R; Bozon, V

Adjei, AA (reprint author), Mayo Clin, Dept Oncol, 200 First St SW, Rochester, MN 55905 USA.; Adjei, AA (reprint author), Roswell Pk Canc Inst, Buffalo, NY 14263 USA.

INVESTIGATIONAL NEW DRUGS, 2017; 35 (1): 47

Abstract

Purpose TAK-733, an investigational, selective, allosteric MEK1/2 inhibitor, has demonstrated antitumor effects against multiple cancer cell lines and......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索